Leerink Partners Reiterates a Buy Rating on NovoCure Limited (NVCR)

NovoCure Limited (NASDAQ:NVCR) is one of the best medical device stocks to buy according to analysts. Leerink Partners analyst Jonathan Chang reiterated a Buy rating on NovoCure Limited (NASDAQ:NVCR) on July 24, setting a price target of $33.00.

A researcher looking through a microscope at a sample in the lab.

The analyst told investors that NovoCure Limited reported solid results for fiscal Q2 2025, exceeding revenue expectations with a total of $158.8 million. This growth was attributed to a rise in active patient numbers across major markets, suggesting solid demand for the products.

Chang added that despite the initial mixed metrics for the launch of Optune Lua in non-small cell lung cancer (NSCLC), prescriptions and active patients underwent a notable growth, suggesting potential for future growth.

NovoCure Limited develops, manufactures, and commercializes Optune to treat a number of solid tumors. The company’s platform is called Tumor Treating Field, and it employs electric fields tuned to specific frequencies to disrupt solid tumor cancer cell division.

READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now.

This article is originally published at Insider Monkey.